Adeno-associated virus serotype 2 capsid variants for improved liver-directed gene therapy.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
received:
09
02
2022
accepted:
07
08
2022
pubmed:
18
8
2022
medline:
22
2
2023
entrez:
17
8
2022
Statut:
ppublish
Résumé
Current liver-directed gene therapies look for adeno-associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted in potent liver targeting variants with one first vector in human clinical trials, modifying natural serotypes by peptide insertion has so far been less successful. Here, we now report on two capsid variants, MLIV.K and MLIV.A, both derived from a high-throughput in vivo AAV peptide display selection screen in mice. The variants transduce primary murine and human hepatocytes at comparable efficiencies, a valuable feature in clinical development, and show significantly improved liver transduction efficacy, thereby allowing a dose reduction, and outperform parental AAV2 and AAV8 in targeting human hepatocytes in humanized mice. The natural heparan sulfate proteoglycan binding ability is markedly reduced, a feature that correlates with improved hepatocyte transduction. A further property that might contribute to the improved transduction efficacy is the lower capsid melting temperature. Peptide insertion also caused a moderate change in sensitivity to human sera containing anti-AAV2 neutralizing antibodies, revealing the impact of epitopes located at the basis of the AAV capsid protrusions. In conclusion, MLIV.K and MLIV.A are AAV peptide display variants selected in immunocompetent mice with improved hepatocyte tropism and transduction efficiency. Because these features are maintained across species, MLIV variants provide remarkable potential for translation of therapeutic approaches from mice to men.
Sections du résumé
BACKGROUND AND AIMS
Current liver-directed gene therapies look for adeno-associated virus (AAV) vectors with improved efficacy. With this background, capsid engineering is explored. Whereas shuffled capsid library screenings have resulted in potent liver targeting variants with one first vector in human clinical trials, modifying natural serotypes by peptide insertion has so far been less successful. Here, we now report on two capsid variants, MLIV.K and MLIV.A, both derived from a high-throughput in vivo AAV peptide display selection screen in mice.
APPROACH AND RESULTS
The variants transduce primary murine and human hepatocytes at comparable efficiencies, a valuable feature in clinical development, and show significantly improved liver transduction efficacy, thereby allowing a dose reduction, and outperform parental AAV2 and AAV8 in targeting human hepatocytes in humanized mice. The natural heparan sulfate proteoglycan binding ability is markedly reduced, a feature that correlates with improved hepatocyte transduction. A further property that might contribute to the improved transduction efficacy is the lower capsid melting temperature. Peptide insertion also caused a moderate change in sensitivity to human sera containing anti-AAV2 neutralizing antibodies, revealing the impact of epitopes located at the basis of the AAV capsid protrusions.
CONCLUSIONS
In conclusion, MLIV.K and MLIV.A are AAV peptide display variants selected in immunocompetent mice with improved hepatocyte tropism and transduction efficiency. Because these features are maintained across species, MLIV variants provide remarkable potential for translation of therapeutic approaches from mice to men.
Identifiants
pubmed: 35976053
pii: 01515467-202303000-00011
doi: 10.1002/hep.32733
pmc: PMC9936986
doi:
Substances chimiques
Peptides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
802-815Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of American Association for the Study of Liver Diseases.
Références
ASGCT. Gene, Cell, and RNA Therapy Landscape [Internet]. Q2 2021 Quarterly Data Report. https://asgct.org/global/documents/asgct‐pharma‐intelligence‐quarterly‐report‐q1‐2021.aspx (2021). Accessed 6 Feb 2022.
Keeler AM, Flotte TR. Recombinant adeno‐associated virus gene therapy in light of luxturna (and Zolgensma and Glybera): where are we, and how did we get here? Annu Rev Virol. 2019;6:601–21.
Croteau SE, Wang M, Wheeler AP. 2021 clinical trials update: innovations in hemophilia therapy. Am J Hematol. 2021;96:128–44.
Rodríguez‐Márquez E, Meumann N, Büning H. Adeno‐associated virus (AAV) capsid engineering in liver‐directed gene therapy. Expert Opin Biol Ther. 2021;21:749–66.
Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, et al. Prevalence of serum IgG and neutralizing factors against adeno‐associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21:704–12.
Levy HC, Bowman VD, Govindasamy L, McKenna R, Nash K, Warrington K, et al. Heparin binding induces conformational changes in adeno‐associated virus serotype 2. J Struct Biol. 2009;165:146–56.
Pillay S, Meyer NL, Puschnik AS, Davulcu O, Diep J, Ishikawa Y, et al. An essential receptor for adeno‐associated virus infection. Nature. 2016;530:108–12.
Dudek AM, Zabaleta N, Zinn E, Pillay S, Zengel J, Porter C, et al. GPR108 is a highly conserved AAV entry factor. Mol Ther. 2020;28:367–81.
Thomas CE, Storm TA, Huang Z, Kay MA. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno‐associated virus vectors. J Virol. 2004;78:3110–22.
Rossi A, Dupaty L, Aillot L, Zhang L, Gallien C, Hallek M, et al. Vector uncoating limits adeno‐associated viral vector‐mediated transduction of human dendritic cells and vector immunogenicity. Sci Rep. 2019;9:3631.
Wang J, Xie J, Lu H, Chen L, Hauck B, Samulski RJ, et al. Existence of transient functional double‐stranded DNA intermediates during recombinant AAV transduction. Proc Natl Acad Sci. 2007;104:13104–9.
Lisowski L, Dane AP, Chu K, Zhang Y, Cunningham SC, Wilson EM, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature. 2014;506:382–6.
Paulk NK, Pekrun K, Zhu E, Nygaard S, Li B, Xu J, et al. Bioengineered AAV capsids with combined high human liver transduction in vivo and unique humoral seroreactivity. Mol Ther. 2018;26:289–303.
Cabanes‐Creus M, Navarro RG, Zhu E, Baltazar G, Liao SHY, Drouyer M, et al. Novel human liver‐tropic AAV variants define transferable domains that markedly enhance the human tropism of AAV7 and AAV8. Mol Ther ‐ Methods Clin Dev. 2022;24:88–101.
High KA, George LA, Eyster ME, Sullivan SK, Ragni MV, Croteau SE, et al. A phase 1/2 trial of investigational Spk‐8011 in hemophilia a demonstrates durable expression and prevention of bleeds. Blood. 2018;132:487.
Schmitz V, Tirado‐Ledo L, Tiemann K, Raskopf E, Heinicke T, Ziske C, et al. Establishment of an orthotopic tumour model for hepatocellular carcinoma and non‐invasive in vivo tumour imaging by high resolution ultrasound in mice. J Hepatol. 2004;40:787–91.
Haupenthal J, Bihrer V, Korkusuz H, Kollmar O, Schmithals C, Kriener S, et al. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Neoplasia. 2012;14:410–9.
Perabo L, Büning H, Kofler DM, Ried MU, Girod A, Wendtner CM, et al. In vitro selection of viral vectors with modified tropism: the adeno‐associated virus display. Mol Ther. 2003;8:151–7.
Zhang L, Rossi A, Lange L, Meumann N, Koitzsch U, Christie K, et al. Capsid engineering overcomes barriers toward adeno‐associated virus vector‐mediated transduction of endothelial cells. Hum Gene Ther. 2019;30:1284–96.
LeCluyse EL, Alexandre E. Isolation and culture of primary hepatocytes from resected human liver tissue. Methods Mol Biol. 2010;640:57–82.
Yuan Q, Loya K, Rani B, Möbus S, Balakrishnan A, Lamle J, et al. MicroRNA‐221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology. 2013;57:299–310.
Schuettrumpf J, Herzog RW, Schlachterman A, Kaufhold A, Stafford DW, Arruda VR. Factor IX variants improve gene therapy efficacy for hemophilia B. Blood. 2005;105:2316–2323.
Milanov P, Ivanciu L, Abriss D, Quade‐Lyssy P, Miesbach W, Alesci S, et al. Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice. Blood. 2012;119:602–11.
Cabanes‐Creus M, Westhaus A, Navarro RG, Baltazar G, Zhu E, Amaya AK, et al. Attenuation of heparan sulfate proteoglycan binding enhances in vivo transduction of human primary hepatocytes with AAV2. Mol Ther Methods Clin Dev. 2020;17:1139–54.
Pavlou M, Schön C, Occelli LM, Rossi A, Meumann N, Boyd RF, et al. Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders. EMBO Mol Med. 2021;13:e13392.
Leaver‐Fay A, Tyka M, Lewis SM, Lange OF, Thompson J, Jacak R, et al. ROSETTA3: an object‐oriented software suite for the simulation and design of macromolecules. In: Methods Enzymol. Volume 487. London: Elsevier; 2011. p. 545–74.
Song Y, DiMaio F, Wang RYR, Kim D, Miles C, Brunette T, et al. High‐resolution comparative modeling with RosettaCM. Structure. 2013;21:1735–42.
Fleishman SJ, Leaver‐Fay A, Corn JE, Strauch EM, Khare SD, Koga N, et al. RosettaScripts: a scripting language interface to the Rosetta macromolecular modeling suite. PLoS One. 2011;6:e20161.
Zhang R, Cao L, Cui M, Sun Z, Hu M, Zhang R, et al. Adeno‐associated virus 2 bound to its cellular receptor AAVR. Nat Microbiol. 2019;4:675–82.
Tyka MD, Keedy DA, André I, DiMaio F, Song Y, Richardson DC, et al. Alternate states of proteins revealed by detailed energy landscape mapping. J Mol Biol. 2011;405:607–18.
Nance ML, Labonte JW, Adolf‐Bryfogle J, Gray JJ. Development and Evaluation of GlycanDock: a protein–glycoligand docking refinement algorithm in Rosetta. J Phys Chem B. 2021;125:6807–20.
Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 2021;30:70–82.
Singal AK, Kodali S, Vucovich LA, Darley‐Usmar V, Schiano TD. Diagnosis and treatment of alcoholic hepatitis: a systematic review. Alcohol Clin Exp Res. 2016;40:1390–402.
Tian C, Kasavajhala K, Belfon KAA, Raguette L, Huang H, Migues AN, et al. ff19SB: amino‐acid‐specific protein backbone parameters trained against quantum mechanics energy surfaces in solution. J Chem Theory Comput. 2020;16:528–5252.
Case DA, Aktulga HM, Belfon KAA, Ben‐Shalom IY, Brozell SR, Cerutti DS, et al. Amber 2021. San Francisco: University of California, San Francisco; 2021.
Roe DR, Cheatham TE. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput. 2013;9:3084–95.
Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14:33–8.
Au HKE, Isalan M, Mielcarek M. Gene therapy advances: a meta‐analysis of AAV usage in clinical settings. Front Med. 2022;8:809118.
Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Büning H, et al. Genetic modifications of the adeno‐associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther. 2003;10:2139–47.
Opie SR, Warrington KH, Agbandje‐McKenna M, Zolotukhin S, Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno‐associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol. 2003;77:6995–7006.
Westhaus A, Cabanes‐Creus M, Jonker T, Sallard E, Navarro RG, Zhu E, et al. AAV‐p40 bioengineering platform for variant selection based on transgene expression. Hum Gene Ther. 2022;33:664–82.
Raupp C, Naumer M, Muller OJ, Gurda BL, Agbandje‐McKenna M, Kleinschmidt JA. The threefold protrusions of adeno‐associated virus type 8 are involved in cell surface targeting as well as postattachment processing. J Virol. 2012;86:9396–408.
Havlik LP, Simon KE, Smith JK, Klinc KA, Tse LV, Oh DK, et al. Coevolution of adeno‐associated virus capsid antigenicity and tropism through a structure‐guided approach. J Virol. 2020;94:e00976‐20.
Cabanes‐Creus M, Hallwirth CV, Westhaus A, Ng BH, Liao SHY, Zhu E, et al. Restoring the natural tropism of AAV2 vectors for human liver. Sci Transl Med. 2020;12:eaba3312.
Kern A, Schmidt K, Leder C, Müller OJ, Wobus CE, Von Der Lieth CW, et al. Identification of a heparin‐binding motif on adeno‐associated virus type 2 capsids. J Virol. 2003;77:11072–81.
Summerford C, Samulski RJ. Membrane‐associated heparan sulfate proteoglycan is a receptor for adeno‐associated virus type 2 virions. J Virol. 1998;72:1438–45.
Uhrig S, Coutelle O, Wiehe T, Perabo L, Hallek M, Büning H. Successful target cell transduction of capsid‐engineered rAAV vectors requires clathrin‐dependent endocytosis. Gene Ther. 2012;19:210–8.
Sallach J, Di Pasquale G, Larcher F, Niehoff N, Rübsam M, Huber A, et al. Tropism‐modified AAV vectors overcome barriers to successful cutaneous therapy. Mol Ther. 2014;22:929–39.
Tabebordbar M, Lagerborg KA, Stanton A, King EM, Ye S, Tellez L, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle‐directed gene delivery across species. Cell. 2021;184:4919–38.e22.
Gehrke M, Diedrichs‐Möhring M, Bogedein J, Büning H, Michalakis S, Wildner G. Immunogenicity of novel AAV capsids for retinal gene therapy. Cell. 2022;11:1881.
Bennett A, Keravala A, Makal V, Kurian J, Belbellaa B, Aeran R, et al. Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2. J Struct Biol. 2020;209:107433.